Understand the source comparison
ARA-290 Myths Debunked: Comparison Table
The table below contrasts common online claims about ARA-290 with the actual evidence base from peer-reviewed trials and preclinical studies. ARA-290 regenerates damaged nerves Reduces inflammatory cytokine expression and modulates macrophage phenotype. Does n
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below contrasts common online claims about ARA-290 with the actual evidence base from peer-reviewed trials and preclinical studies.
- ARA-290 regenerates damaged nerves
- Reduces inflammatory cytokine expression and modulates macrophage phenotype. Does not rebuild axons or myelin
- Preclinical only (rat models)
- Tissue protection ≠ regeneration
- Proven effective for diabetic neuropathy
- One Phase 2a trial (n=36) failed to meet primary endpoint (corneal nerve fiber density)
- 2014 Diabetes Care trial
- Underpowered trial with negative result
- Works as well as full-length EPO without side effects
- Selectively activates innate repair receptor without erythropoiesis. Mechanism distinct from EPO
- Multiple preclinical studies
- True mechanistic distinction, but efficacy not equivalent
- FDA-approved for neuropathy treatment
- No regulatory approval in any country as of 2026
- N/A
- Available only as research compound
- Reduces neuropathic pain consistently
- One trial (sarcoidosis neuropathy, n=28) showed statistically significant pain reduction; diabetic trial did not
- 2015 Molecular Medicine trial
- Effect may be condition-specific
- Safe with no significant adverse events
- Injection site reactions most common; no serious adverse events in published trials
- Phase 1/2 safety data
- Short-term safety profile acceptable
- Myth 3: ARA-290 is as effective as full-length EPO for tissue protection. Reality: while both activate the EPO-R/CD131 complex, full-length EPO also activates homodimeric EPO receptors that drive erythropoiesis, leading to polycythemia risk in chronic dosing. ARA-290 avoids this specific risk, but the two compounds have not been directly compared in head-to-head human trials for any tissue-protective indication. Preclinical models suggest similar anti-inflammatory effects at equimolar doses, but translating rodent pharmacokinetics and receptor density to human physiology is fraught with uncertainty.
- Our team has reviewed peptide synthesis protocols and purity testing data for compounds like ARA-290, BPC-157, and Thymosin Alpha-1 across hundreds of research applications. The pattern is consistent: peptides with plausible preclinical mechanisms generate outsized expectations that early-phase human data cannot support. ARA-290 fits this profile exactly.